A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression.
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Selegiline (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Somerset Pharmaceuticals
- 28 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Feb 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 02 Oct 2007 New trial record.